Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 259, Issue -, Pages 115657
Publisher
Elsevier BV
Online
2023-07-21
DOI
10.1016/j.ejmech.2023.115657
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
- (2022) Yuto Unoh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
- (2022) Bao-Xue Quan et al. Nature Microbiology
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation
- (2022) Jaeyong Lee et al. Nature Communications
- Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
- (2022) Sho Iketani et al. NATURE
- Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
- (2022) Qing Xiong et al. NATURE
- SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
- (2021) Jingxin Qiao et al. SCIENCE
- The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities
- (2021) Marco Robello et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- (2020) Roujian Lu et al. LANCET
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- hERG toxicity assessment: Useful guidelines for drug design
- (2020) Amanda Garrido et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Remdesivir: First Approval
- (2020) Yvette N. Lamb DRUGS
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Telaprevir: Changing the standard of care of chronic hepatitis C
- (2013) AK Rajani et al. Journal of Postgraduate Medicine
- Screening technologies for ion channel drug discovery
- (2010) Georg C Terstappen et al. Future Medicinal Chemistry
- Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor
- (2010) Ashok Arasappan et al. ACS Medicinal Chemistry Letters
- Discovery and Structure−Activity Relationship of P1−P3Ketoamide Derived Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease
- (2008) Srikanth Venkatraman et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started